Related Experiment Video

Updated: Jun 6, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children

David W Hutton1, Lisa A Prosser1,2, Angela M Rose2

  • 1Department of Health Management and Policy, School of Public Health.

Pediatrics
|November 25, 2024
PubMed

Insights

Nirsevimab is a cost-effective option for preventing respiratory syncytial virus (RSV) hospitalizations in infants. It offers significant value, especially for high-risk infants and in scenarios with higher RSV-related costs.

Area of Science:

  • Public Health
  • Health Economics
  • Pediatric Infectious Diseases

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of infant hospitalizations in the U.S.
  • Nirsevimab is recommended for infants during their first RSV season and high-risk children in their second season.
  • Evaluating the cost-effectiveness of nirsevimab is crucial for public health policy.

Purpose of the Study:

  • To assess the cost-effectiveness of nirsevimab for all infants in their first RSV season.
  • To evaluate the cost-effectiveness of nirsevimab for high-risk children in their second RSV season.
  • To analyze societal outcomes and identify influential factors in nirsevimab's cost-effectiveness.

Main Methods:

  • A simulation model was used to estimate healthcare utilization and deaths from RSV.
  • Data were sourced from published literature, FDA documents, and surveillance data.
  • Societal outcomes were evaluated over a lifetime with 3% discounting.

Main Results:

  • Averting 107,253 outpatient visits, 38,204 ED visits, and 14,341 hospitalizations annually if half the birth cohort receives nirsevimab.
  • Cost-effectiveness was $153,517 per QALY saved for nirsevimab in the first season.
  • Cost-effectiveness was $308,468 per QALY saved for high-risk children in the second season.

Conclusions:

  • Nirsevimab is a potentially cost-effective intervention for infants against RSV.
  • Cost-effectiveness is particularly favorable in populations with higher RSV risks and associated healthcare costs.
  • Sensitivity analyses confirmed key drivers of cost-effectiveness, including RSV hospitalization costs and nirsevimab's price.
Abstract

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.4K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
352
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
310
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
174
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
173
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
126